Boston Oncology is an integrated pharmaceutical company purpose-built to expand access to the medicines that shape health across a lifetime.
Across the GCC and wider MENA region, five chronic and complex health categories together represent a chronic-risk burden estimated at nearly USD 1 trillion* over the next 10–15 years.
This burden is not confined to a moment of diagnosis. It builds over time—from risks that can be addressed earlier, through conditions requiring long-term management, to complex diseases demanding sustained treatment.
*Boston Oncology management estimate based on a synthesis of publicly available regional disease-burden, healthcare-cost, and productivity data. Represents projected aggregate direct and indirect costs across the GCC and wider MENA region over the next 10–15 years.
Boston Oncology’s Lifetime Health Stack™ organizes our portfolio response across five connected health layers—anchored in Cancer, extending through Chronic Inflammation, Metabolic Health, and Lipids and Cardiovascular Risk, with Neurocognitive Health defining the next frontier.
One coordinated portfolio strategy shaped around practical goals: earlier intervention, more reliable access, and treatment that can be sustained over time.
A launched incretin medicine and broader incretin franchise, a long-acting lipid-lowering program, and a monoclonal-antibody biosimilar platform bring prevention, long-term disease management, and complex treatment together in one regional portfolio.
Across these five categories, most of the medicines needed to change the trajectory of disease already exist and have been approved in other markets.
The gap is not scientific.
What separates medical invention from impact is friction: registration time, budget-impact uncertainty, supply that arrives late or not at all, dosing schedules patients abandon, and conditions no one feels urgency about treating.
Friction is the variable Boston Oncology’s integrated platform is built to move.
Because it was the hardest category to get right—requiring command of complex biologics, aseptic manufacturing, high-touch regulatory pathways, tender economics, and dependable supply.
Building our platform to that standard created the operating foundation now being applied across the Lifetime Health Stack.
Market entry is a milestone. Market expansion is an operating discipline.
Boston Oncology brings regulatory strategy, manufacturing, and commercial execution together in one localized platform—giving proven medicines the foundation to realize their full clinical and market potential.
Through embedded commercial teams, regulatory fluency, and supply reliability, we transform fragmented demand into sustained adoption across healthcare systems.
Source: Boston Oncology internal market, utilization, and hospital-adoption records. Adalimumab market share, tocilizumab utilization growth, and enoxaparin first-line adoption reflect company analysis of the relevant Saudi government-hospital channels and reporting periods available for each product.
Located in the Kingdom of Saudi Arabia, Boston Oncology Arabia is the model in action. Anchored by local manufacturing in Sudair and embedded across Saudi procurement and hospital systems, the company transforms local infrastructure into national reach—and provides a proven foundation for expansion across the GCC and MENA.
Boston Oncology Arabia operates advanced cGMP pharmaceutical manufacturing facilities designed for the scalable production of complex medicines, including biosimilars, peptides, specialty injectables, and generics.
With shared infrastructure spanning vials, prefilled syringes, cartridges, and pens, the same qualified manufacturing base can support medicines across multiple Lifetime Health Stack layers—without requiring a separate manufacturing system for each new health priority.
In the Gulf, most localization routes stop at import and secondary packaging. Boston Oncology goes further—filling cartridges and assembling pens within the same qualified site.
This scarce capability extends localization through the finished delivery system and establishes a durable manufacturing position in metabolic health.
From the medicines we select to the way we manufacture and deliver them, every decision begins with what people need across a lifetime: earlier intervention, reliable management of chronic risk, and sustained access through complex treatment.
That responsibility demands urgency, precision, and accountability at every step.
Boston Oncology Arabia has received Good Manufacturing Practice (GMP) certification from the Saudi Food and Drug Authority (SFDA) for its pharmaceutical manufacturing facility in Sudair Industrial City.
H.E. Eng. Khalil bin Ibrahim bin Salamah, Vice Minister of Industry and Mineral Resources for Industrial Affairs, and Eng. Majed bin Rafed Al-Argoubi, CEO of the Saudi Authority for Industrial Cities and Technology Zones (MODON), joined Boston Oncology Arabia leaders and team members at the company’s Sudair manufacturing facility.
A global benchmark of excellence in finance, ethics, and professional development.
Connect with our team to explore licensing, commercialization, and market expansion opportunities.
Find medicine, safety, and support information for patients and caregivers.
